Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing innovative treatments for central nervous system (CNS) diseases. The company is advancing its lead product candidate, d-Methadone (also known as esmethadone or REL-1017), a novel NMDA receptor antagonist currently in late-stage development as an adjunctive treatment for major depressive disorder in adults. Additionally, Relmada is working on several other drug formulations, including LevoCap ER, an abuse-resistant sustained-release version of levorphanol; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of the local anesthetic mepivacaine, which has received orphan drug designation. Founded in 2004, Relmada Therapeutics aims to address significant unmet medical needs in the treatment of CNS disorders.